Groenhuysen Wilhelmus Cm - Feb 27, 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Operating Officer
Signature
Steven Robbins, as attorney in fact for Groenhuysen, Wilhelmus CM
Stock symbol
NVCR
Transactions as of
Feb 27, 2024
Transactions value $
$1,901,811
Form type
4
Date filed
2/29/2024, 04:28 PM
Previous filing
Sep 5, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $38.10 +3 +0% $12.69 210K Dec 31, 2023 Direct F1, F2
transaction NVCR Ordinary Shares Award $767K +47K +22.42% $16.30 257K Feb 27, 2024 Direct F3
transaction NVCR Ordinary Shares Sale -$37.2K -2.3K -0.9% $16.14 255K Feb 28, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Stock Options (Right to buy) Award $1.17M +71.9K $16.30 71.9K Feb 27, 2024 Ordinary Shares 71.9K $16.30 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023.
F3 Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F4 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F5 Options to buy 71,920 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.